Health ❯ Public Health ❯ Obesity

Weight Management

GLP-1 Drugs Medications Weight-loss Drugs Pharmaceuticals Healthcare Services Medication Use Weight Loss Drugs GLP-1 Medications Impact on Industries Anti-Obesity Medications

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Phase 3 trials are set to begin this quarter following 48-week topline data showing large placebo-adjusted weight loss.

Trump Cites 'Very Fat' Friend's Ozempic Story to Decry Price Gap

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

U.S. Obesity Rate Drops to 37% as GLP-1 Use Surges, Gallup Finds

Mounjaro Climbs to No. 2 in India by Sales as Wales Maps NHS Path for Weight‑Loss Drugs

GLP-1 Debate Intensifies: Australia Considers Subsidies as India Warns of Misuse Risks

UK and Eli Lilly Unveil £85m Pilot for Pharmacy and Digital Delivery of Weight-Loss Injections

Ultra-Processed Foods Slash Weight Loss and Fuel Cravings, Study Shows

UK Launches NHS 10-Year Plan to Expand Free Weight-Loss Injections

Turkey's Public BMI Campaign Draws Privacy and Dignity Concerns

Eli Lilly Launches Mounjaro in India to Address Obesity and Diabetes

U.S. Obesity Rates Decline for First Time in Over a Decade

UK Government Trials Weight-Loss Jabs to Tackle Unemployment

U.S. Obesity Rates Decline as Weight-Loss Drugs Gain Popularity